Analyst reports.
This information is provided for information purposes only. The opinions, estimates, forecasts or any analysis do not represent the opinions, forecasts, or any analysis of our Company or management or staff. We do not by its reference imply any concurrence with the independently provided opinions, estimates or forecasts.
Analyst Reports
Analyst Reports
September 10th 2023
CLSA - FY24 a pivotal year with key readouts ahead and cash runway to CY26. Mtn Buy, A$0.95 Tgt (Analyst: Andrew Paine)
August 31st 2023
Jefferies - FY23: I Say A Little Prayer; Mtn Buy and A$1 tgt (Analyst: Dr David Stanton)
August 28th 2023
Baird - Efti Continues to Look More Promising than Anti-TIGIT; $7 tgt (Analysts: Joel L. Beatty and Benjamin E. Paluch)
August 2nd 2023
Baird - Unique LAG-3 Agent with Fast Track Designation; Initiate OP, $7 tgt
July 3rd 2023
Bell Potter - Cash Secured. Readouts 2H CY2023. (Analyst: Thomas Wakim)
May 29th 2023
Petra Capital - 2L HNSCC detailed results: Wait for ASCO; Retain Buy, A$1.28 tgt (Analyst: Tanushree Jain)
May 25th 2023
Petra Capital - Triple combo data in NSCLC shows promise; Retain Buy, A$1.28 tgt (Analyst: Tanushree Jain)
May 24th 2023
Bell Potter - Efti's Efficacy - Strong Rationale for Prioritising NSCLC (Analyst: Thomas Wakim)
May 18th 2023
Petra Capital - First OS look in NSCLC impresses; Retain Buy, A$1.28 tgt (Analyst: Tanushree Jain)
May 17th 2023
Maxim Group: Efti+Keytruda Leads to Positive Survival Data in 1L Lung Cancer; Raise tgt to $10, mtn Buy (Jason McCarthy, PhD)
May 17th 2023
CLSA - Efti & Keytruda’s excellent adventure; OS data shows meaningful benefit in NSCLC, without need for chemo (Analyst: Andrew Paine)
April 28th 2023
Petra Capital - Immutep Ltd (IMM) - 3QFY23 – Clinical Progress on all fronts; Retain Buy, A$1.28 tgt (Analyst: Tanushree Jain)
April 19th 2023
Maxim Group - New Efti Trial Announced in Sarcoma; Moving into Neoadjuvant Setting; Buy, $8 tgt (Jason McCarthy, PhD)
April 5th 2023
Petra Capital - Immutep Ltd (IMM) - Efti activity in PD-1 refractory patients re-confirmed; Reit Buy, A$1.28 Tgt (Analyst: Tanushree Jain)
April 3rd 2023
Ladenburg Thalmann - Final 2L Lung Data Looks Fine; the Focus Is on 1L NSCLC; Reit Buy, $8.30 Tgt (Dr Ahu Demir)
March 14th 2023
Maxim Group - New P2/3 AIPAC-003 Study Initiated with More Aggressive Dosing & OS Primary in Breast Cancer; Buy, $8 tgt (Jason McCarthy, PhD)
March 8th 2023
CLSA - Immutep: Defining year. Cash-runway through late stage head & neck readout and Lung Ph3 start. Retain Buy, A$1.25 tgt (Andrew Paine)
February 28th 2023
Petra Capital - Immutep Limited (IMM) - Accelerating clinical and manufacturing work (Analyst: Tanushree Jain)
February 10th 2023
Petra Capital - Immutep - The stage is set for an explosive 2023; Reit Buy & lift TP by 8% to A$1.30 (Analyst: Tanushree Jain)
January 31st 2023
Ladenburg Thalmann - One Asset and Multiple Opportunities; Reit Buy and $8.30 Target (Dr Ahu Demir)
December 14th 2022
Bell Potter - Analyst Outlook & Stock Picks for 2023
December 5th 2022
Jefferies - Immutep (IMM AU, BUY): Expanding into Urothelial Cancer (Analyst: Dr David Stanton)
November 29th 2022
CLSA Equity Research - Immutep (IMM) announces a new collaboration with Merck KGaA and Pfizer for a Ph 1 clinical trials for metastatic urothelial cancer (INSIGHT-005) (ASX:IMM) (Analyst: Andrew Paine)
November 29th 2022
Petra Capital - Immutep Limited (IMM) - New clinical trial collaboration with Merck KGaA/Pfizer for Phase 1 with efti in urothelial cancer, a positive with more to come (Analyst: Tanushree Jain)
November 16th 2022
Petra Capital - Immutep Limited (IMM) - Stellar NSCLC showing at SITC, registrational trial in 2H23 (Analyst: Tanushree Jain)
November 11th 2022
Ladenburg Thalmann - SITC: Efti Is Active in NSCLC, Adaptive Registration Trial Is Next; Reaffirm Buy (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)
November 11th 2022
CLSA Equity Research - Unrealised value - Lung data update supportive of overall value realisation into CY23 (ASX:IMM) (Analyst: Andrew Paine)
November 10th 2022
Jefferies - IMM AU Releases Positive SITC Data (ASX: IMM) (Analyst: Dr David Stanton)
November 10th 2022
Maxim Group - Efti in 1L Lung Cancer at SITC – Response Rates are Favorable, but it's the Duration of Response that Impresses (Analyst: Jason McCarthy)
November 7th 2022
Maxim Group - Late-Breaking Abstract for Eftilagimod Selected for SITC Press Conference (Analyst: Jason McCarthy)
October 26th 2022
Ladenburg Thalmann - NSCLC Is the Focus for Late-stage Development; Reiterate Buy and $8.30 PT (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)
October 25th 2022
Petra Capital - Immutep Limited (IMM) - TACTIcal IO Positioning - Hard to Ignore; Initiating with Buy rating and A$1.19 Target (Analyst: Tanushree Jain)
October 6th 2022
CLSA Equity Research - PD-L1 competition good for efti - GSK’s PD-L1 result highlights increasing competition for Keytruda (ASX:IMM) (Analyst: Andrew Paine)
October 5th 2022
Maxim Group - Looking Towards SITC In November; Eftilagimod Abstracts Accepted (Analyst: Jason McCarthy)
October 4th 2022
CLSA Equity Research - Tracking positively - FDA NSCLC Fast Track designation follows promising data readout (ASX:IMM) (Analyst: Andrew Paine)
September 5th 2022
CLSA Equity Research - Immutep : On to the main acts (ASX:IMM) (Analyst: Andrew Paine)
August 31st 2022
CLSA Equity Research - Immutep FY22 Result: Cash runway to early-CY24; may prioritise 1L NSCLC trial (which is in combo with Keytruda) (ASX:IMM) (Analyst: Andrew Paine)
August 31st 2022
Jefferies - Immutep Ltd | BUY : IMM AU | AUD0.29 | PT: AUD1.00 (AUD0.90) | % to PT: +245% - FY22: Run (ASX: IMM) (Analyst: Dr David Stanton)
August 2nd 2022
Maxim Group - Interim Data from TACTI-002 Study to be Presented at World Conference on Lung Cancer, Aug 6-9 (Analyst: Jason McCarthy)
August 1st 2022
Ladenburg Thalmann - One Drug, Multiple Late-stage Opportunities; Reiterate Buy Rating (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)
July 22nd 2022
Jefferies - IMM AU - Increased Importance of TACTI-003 for MRK in HNSCC (ASX: IMM) (Analyst: Dr David Stanton)
June 7th 2022
CLSA Equity Research - Not Lag-ging - Ph2 data support progression to Ph3 on positive results (ASX:IMM) (Analyst: Andrew Paine)
June 7th 2022
Bell Potter - IMM - a very viable big pharma target (Analyst: Dr Tara Speranza)
June 6th 2022
Maxim Group - Positive 1L Lung Cancer Data for Efti/Pembro at ASCO; Webcast Today at 6pm ET (Analyst: Jason McCarthy)
June 4th 2022
Jefferies - IMM AU releases ASCO Data (ASX: IMM) (Analyst: Dr David Stanton)
May 27th 2022
CLSA Equity Research - Another promising readout - 1L NSCLC readout shows slight increase in ORR in larger patient cohort (ASX:IMM) (Analyst: Andrew Paine)
May 12th 2022
Maxim Group - Disappointing Data for TIGIT; Nice Set up for Immutep’s soluble LAG-3 in 1L NSCLC? ASCO is Next (Analyst: Dr Naureen Quibria)
May 5th 2022
CLSA Equity Research - Raising the profile - AIPAC data continues to support MOA ahead of key conference (ASX:IMM) (Analyst: Andrew Paine)
May 5th 2022
Bell Potter - Breast cancer trial data supports mechanism of action (Analyst: Dr Tara Speranza)
March 25th 2022
Ladenburg Thalmann - ELCC Abstract: First Data in 2L NSCLC from TACTI-002; Reiterate Buy (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)
March 24th 2022
Jefferies - New TACTI-002 Data - Efficacy in Line, SE Lower (ASX: IMM) (Analyst: Dr David Stanton)
March 24th 2022
CLSA Equity Research - Keep on keeping on - 2L NSCLC within expectations, but 1L HNSCC & NSCLC remain focus (ASX:IMM) (Analyst: Andrew Paine)
March 21st 2022
Ladenburg Thalmann - The Key Approval Arrived in the LAG-3 Arena (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)
March 20th 2022
CLSA Equity Research - LAG-3 launch pad - FDA approval of LAG-3 therapy a key milestone for the sector (ASX:IMM) (Analyst: Andrew Paine)
March 19th 2022
Jefferies - First LAG-3 Checkpoint Inhibitor Approved (ASX: IMM) (Analyst: Dr David Stanton)
March 1st 2022
CLSA Equity Research - Hitchin’ a ride - BMS’ LAG-3 FDA approval could see increased interest in I-O sector (ASX:IMM) (Analyst: Andrew Paine)
February 23rd 2022
Maxim Group - Reports Half-Year Results; Eyeing the First External LAG-3 Approval from Bristol (Analyst: Dr Naureen Quibria)
January 31st 2022
Ladenburg Thalmann - Our Top Picks for 2022 (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)
December 1st 2021
Jefferies - Turning Cold Cancers Hot – Initiating at Buy - TP to $A1 (ASX: IMM) (Analyst: Dr Dave Stanton)
November 23rd 2021
Taylor Collison - AIPAC disappoints but TACTI-003 adding value - Increasing TP to $A1.36 (from $A1.19) (ASX: IMM) (Analyst: Dr Dennis Hulme)
November 10th 2021
CLSA Equity Research - Not worth less today than yesterday - Increasing TP to A$1.33 (from A$1.19) (ASX:IMM) (Analyst: Andrew Paine)
October 16th 2021
CLSA Equity Research - On the right pathway - Initiating coverage with a Buy Rating of A$1.19 TP (ASX:IMM) (Analyst: Andrew Paine)
August 3rd 2021
Ladenburg Thalmann - New Age Immune Regulator - Initiate with a Buy Rating of US$8.30 TP (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)
July 14th 2021
Bell Potter - Creating Value with Phase 3 around the corner – Increasing TP to AUD 1.00 (from AUD 0.85)
July 6th 2021
Taylor Collison - Efti development program expanded - Increasing TP to AUD 1.19 (from AUD 0.85)
April 9th 2021
Bell Potter - Efti granted Fast Track - A vote of confidence (Analyst: Tanushree Jain)
March 31st 2021
Bell Potter - Validation for LAG-3 arrives (Analyst: Tanushree Jain)
March 6th 2021
Bell Potter - Stage 2 of 2nd line NSCLC patient cohort in Phase 2 TACTI-002 trial starts recruitment (Analyst: Tanushree Jain)
February 25th 2021
Bell Potter - 1H21 Results broadly in-line (Analyst: Tanushree Jain)
February 5th 2021
Bell Potter - Strong balance sheet with several catalysts (Analyst: Tanushree Jain)
January 26th 2021
Alliance Global Partners - Raising PT to $6 from $5; MBC Program Thrown a Lifeline by OS Data as IMMP Shares Find Their Heading for the Year of the Sea Shanty
October 27th 2020
Bell Potter - Efti now tackling COVID-19 (Analyst: Tanushree Jain)
September 17th 2020
Bell Potter - Underappreciated immunotherapy player with leadership in LAG-3 (Analyst: Tanushree Jain)
June 3rd 2020
Bell Potter - ASCO data further builds case for efti+Keytruda, with HNSCC looking more attractive (Analyst: Tanushree Jain)
March 27th 2020
Bell Potter - Phase 2b AIPAC trial results provide path forward in metastatic breast cancer (Analyst: Tanushree Jain tnjain@bellpotter.com.au)
February 18th 2020